MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00432-022-04321-6

Медицинская библиотека · Journal of cancer research and clinical oncology · 2022

Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.

Wen Qing, Ge Jingjing, Lei Yaxin, Zhang Yue, Kong Xiaoshuang, Wang Wenhua, Hou Huting, Wang Zeyuan, Qian Siyu, Ding Mengjie, Dong Meng, Zhu Linan, Zhang Mingzhi, Zhang Xudong, Chen Qingjiang

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) has been regarded as the standard treatment regimen for classical Hodgkin lymphoma. In recent years, ABVD-like regimens, which emerged due to shortages and the lung toxicity of bleomycin or the emergence of immune checkpoint inhibitors and antibody-drug conjugates, may be favorable, but have not yet been tested.

METHODS

We compared the outcomes of ABVD with ABVD-like regimens, which include bleomycin was completely or partially omitted; meanwhile, etoposide or PD-1 inhibitors were added.

RESULTS

5-Year progression-free survival (PFS) was higher for ABVD than ABVD-like regimens in young patients (82.1% vs. 67.0%, p = 0.029), patients with serum beta-2 microglobulin (β2-MG) ≥ 1.85 mg/L (75.8% vs. 57.6%, p = 0.046), and advanced-stage patients with IPS score 4-7(63.1%, 18.3%, p = 0.038). For elderly (60.5% vs.76.1%, p = 0.089), patients with β2-MG < 1.85 mg/L (83.1% vs 76.1%, p = 0.282), and advanced-stage patients with IPS score 0-3(84.6% vs. 81.3%, p = 0.476), 5-year PFS for ABVD did not differ from ABVD-like regimens. Elderly patients treated with bleomycin-free regimens showed a better survival trend compared with ABVD (99.3% vs. 61.3%, p = 0.270).

CONCLUSION

ABVD is superior to ABVD-like regimens in achieving PFS in young patients or patients with poor prognosis including high IPS score and β2-MG level. ABVD-like regimens are as effective as ABVD in elderly or low-risk patients including low IPS score and β2-MG level; elderly patients treated with bleomycin-free regimens exhibit a better survival trend compared with ABVD.

Для цитирования: Wen Qing, Ge Jingjing, Lei Yaxin, Zhang Yue, Kong Xiaoshuang, Wang Wenhua, Hou Huting, Wang Zeyuan, Qian Siyu, Ding Mengjie, Dong Meng, Zhu Linan, Zhang Mingzhi, Zhang Xudong, Chen Qingjiang. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.. Journal of cancer research and clinical oncology. 2022. DOI: 10.1007/s00432-022-04321-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.